Crossland, Denise L.
Denning, Warren L.
Ang, Sonny
Olivares, Simon
Mi, Tiejuan
Switzer, Kirsten
Singh, Harjeet
Huls, Helen
Gold, Kate S.
Glisson, Bonnie S.
Cooper, Laurence J.
Heymach, John V.
Article History
Received: 24 July 2017
Revised: 5 December 2017
Accepted: 5 February 2018
First Online: 6 April 2018
Compliance with ethical standards
:
: The technology described in this report was advanced through research conducted at MD Anderson by LJC. In January 2015, the technology was licensed by MD Anderson for commercial application to ZIOPHARM Oncology, Inc., and Intrexon Corporation, in exchange for equity interests in each of these companies. LJC and some co-authors are eligible to receive equity as a result of the licensing of this technology. On May 7, 2015, LJC was appointed as the Chief Executive Officer at ZIOPHARM. LJC is also a Visiting Scientist at MD Anderson, where he continues to help supervise the development of this technology. The information being reported in this publication is research in which MD Anderson has an institutional financial conflict of interest. Because MD Anderson is committed to the protection of human subjects and the effective management of its financial conflicts of interest in relation to its research activities, MD Anderson has implemented an Institutional Conflict of Interest Management and Monitoring Plan to manage and monitor the conflict of interest with respect to MD Anderson’ s conduct of this research. JVH reports receiving commercial research support from AstraZeneca and is a consultant/advisory board member for AstraZeneca, Boehringer Ingelheim, Genentech, GlaxoSmithKline, and Synta. The remaining authors declare that they have no conflict of interest.